home > news > detailed info

Nemera launches UniSpray, its unidose system primarily for systemic-acting drug administration


Nemera has a proven track record in developing and manufacturing complex Ear Nose and Throat solutions. In line with clear growing market interest in unidose system coupled with promising advantages that nasal route could offer, Nemera is thrilled to extend its portfolio by launching its unidose system, UniSpray, for systemic-acting drug administration to face emergency and crisis.

Other than treating conditions locally, nasal delivery is an attractive option to also administer systemic therapies which may vary from benign to serious health conditions. What’s more, is that the nasal route is not invasive and does not require healthcare professionals’ intervention where patients can selfadminister their remedy with a rapid onset.

UniSpray is a ready-to-use primeless device with single-metered liquid dose delivery. It offers one-handed activation with 360° functionality to face emergency and crisis. Thanks to its ergonomic design, it is intuitive and easy-to-use.

UniSpray is a unidose system concept under development, designed to be robust and compatible with existing marketed primary containers. Through usability analysis and Freedom to Operate assessment, we assure reliability and regulatory compliance of our unidose concept.

Bernhard Rohn, VP Strategy and Marketing, commented: "Nemera has a longstanding experience in the nasal delivery route, focusing until now on multidose pumps. Adding UniSpray to our product range provides additional options for our customers and patients, answering the needs of the single-metered dose spray combination products"

Raphaële Audibert, Global Category Manager – ENT, added: “This is a great milestone for us. The increasing patient preference for nasal drug delivery as a result of easy administration and better efficacy as well as growing adoption of selfadministration practices are some of the key factors driving the growth of the nasal market.”

Come discover UniSpray at CPhI Worldwide in Milan, from 9th to 11th November, at booth 6J42. UniSpray at a glance:

  • Intuitive and robust device with ergonomic finger rest
  • Broad labeling surface
  • Safe and secured with no risk of accidental activation
  • Accelerates time-to-market thanks to possible adaptations to conventional filling lines
  • Equivalent utilization and performance as originators thanks to our in-vitro bioequivalence capability
  • Ready-to-use, primeless device, 360° functionality
  • Compatible with existing primary drug container
  • Single dose liquid delivery device with one accurate 100µL dose
  • Compliant to regulatory exigence
  • Customization possibilities
  • For new and repurposed drug, as well as generics
phone +33 4 74 94 06 54
email 20 avenue de la Gare, 38290 – La Verpilličre, France
Print this page
Send to a friend
News and Press Releases

New Report Uncovers the Extent of Data Integrity Challenges for UK Pharmaceutical Manufacturers

Big data, audit trails, system integration and access privileges are among the most pressing data integrity challenges for pharmaceutical manufacturers, according to a new industry report published by Yokogawa. With many manufacturers already facing historical data integrity challenges, including hybrid systems and ageing equipment, the advent of digital transformation is set to place further pressure on manufacturers looking to remain on the right side of auditors.
More info >>

White Papers

What Your Clinical Study Design Reveals About Your Clinical Packaging Needs

PCI Pharma Services

As the cost and complexities of drug development increase, so do the challenges of global clinical trials. Today’s sponsors must be able to manage and coordinate multiple resources, processes, and locations with speed and accuracy to design effective and efficient clinical trials. Securing a stable supply chain to deal with the uncertainties of clinical trials is critical. One misstep can have a profound impact not only on the cost and time of your trial but also on its overall success.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement